Musculoskeletal
Medicines

Musculoskeletal Medicine Supply for Hospitals & International Buyers

Musculoskeletal diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, osteoporosis, gout and chronic back pain, represent some of the most prevalent and disabling chronic conditions worldwide. The GCC region faces a particularly high burden: lifestyle factors, high-calorie diets and an ageing population have driven sharp increases in both inflammatory arthritis and metabolic bone disease across Saudi Arabia, the UAE and the wider Gulf. Euro Biom supplies medicines to NHS rheumatology departments, private hospitals and international healthcare buyers across GCC countries and Africa.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of symptomatic management across most musculoskeletal conditions. Euro Biom sources oral, topical and injectable formulations including ibuprofen, naproxen, diclofenac, ketoprofen, piroxicam and meloxicam, as well as COX-2 selective agents such as celecoxib and etoricoxib. Where patients require long-term NSAID therapy, co-prescription of a proton pump inhibitor (PPI) such as omeprazole or lansoprazole is standard practice to reduce gastrointestinal risk, and we supply both classes together.

Analgesic medicines for musculoskeletal pain range from paracetamol through to NSAID-based and other non-opioid preparations for chronic pain conditions. Codeine, dihydrocodeine and other opioid analgesics are controlled drugs and fall outside Euro Biom's WDA licence scope. For pain unresponsive to first-line agents, hospitals in Africa and the GCC increasingly require consistent access to non-opioid options in oral and topical forms, and Euro Biom can source these UK-licensed products under its WDA licence for export to licensed importers.

DMARDs and Targeted Therapies

Conventional disease-modifying antirheumatic drugs (DMARDs) form the foundation of rheumatoid arthritis treatment. Euro Biom regularly sources methotrexate, hydroxychloroquine, sulfasalazine and leflunomide in oral formulations, supporting both initiation and maintenance regimens in hospital and outpatient settings.

Advanced DMARD therapies are a rapidly growing area of demand in the GCC, where rheumatology services are expanding significantly. Our specialist supply framework covers oral DMARDs and JAK inhibitors including baricitinib and tofacitinib. Many of these products are not manufactured or distributed locally in GCC or African markets, making UK-sourced supply critical for hospitals establishing or growing rheumatology programmes.

Gout prevalence in the GCC is among the highest in the world, driven by high dietary purine intake, obesity and metabolic syndrome. Euro Biom supplies the full range of urate-lowering and acute gout therapies: allopurinol, febuxostat and colchicine. Reliable access to these medicines is essential for rheumatology and internal medicine departments managing high patient volumes in Saudi Arabia, the UAE and Bahrain.

Osteoporosis management requires a range of medicines across different formulations and administration routes. Euro Biom sources oral bisphosphonates (alendronate, risedronate), intravenous zoledronic acid and strontium ranelate. Calcium and vitamin D supplements used alongside these treatments are also within our regular sourcing range. For hospital pharmacies managing post-menopausal and glucocorticoid-induced osteoporosis, consistent supply of these medicines is a clinical priority.

Muscle relaxants (baclofen, tizanidine, dantrolene), corticosteroid joint injection preparations and local anaesthetic formulations for musculoskeletal use are also available. Euro Biom holds a UK Wholesale Dealer Authorisation (WDA) and operates under Good Distribution Practice (GDP) to ensure compliant, cold-chain-capable supply of temperature-sensitive UK-licensed medicines and injectables to hospitals and licensed importers in the GCC and Africa.